Estimates Revisions XLIE SCIE OTC Markets
Stocks
XLSCF
CH0461929603
Biotechnology & Medical Research
|
Delayed
OTC Markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | - |
| 04-28 | Xlife Sciences Posts FY25 Loss; Revenue Down | MT |
| 04-27 | Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Xlife Sciences AG(XLS)
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
- Stock Market
- Stocks
- XLS Stock
- XLSCF Stock
- Consensus XLIE SCIE
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
